Biphasic insulin aspart compared to biphasic human insulin reduces postprandial hyperlipidemia in patients with Type 2 diabetes

What Was Tested

The paper reports a study of Insulin Aspart, published as a randomized controlled trial.

Insulin also plays an important role in the regulation of postprandial lipid metabolism.

Who Took Part

The abstract describes 12 subjects taking part.

PubMed tags the participants as both men and women.

How the Study Was Run

The researchers set it up as a randomized and crossover study.

Random assignment meant chance, not the researchers, decided who got Insulin Aspart and who got the comparison, which limits bias.

Each person switched between Insulin Aspart and the comparison at some point, usually with a gap in between.

Serum levels of glucose, insulin, C-peptide and triglycerides as well as retinylpalmitate in plasma and chylomicron remnants were determined before and up to 8 hours after the meal.

What Was Measured

Topics PubMed links to this paper include Biphasic Insulins, Chylomicron Remnants, Chylomicrons, Diabetes Mellitus, Type 2, Diterpenes, Hyperlipidemias and Hypoglycemic Agents.

What This Means in Plain Language

The paper is a randomized and crossover study of Insulin Aspart in 12 subjects.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 4 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2005 (Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association), a journal based in Germany.

More context: the Insulin Aspart compound page, all human trials.